Abstract
Angiogenic biomarkers have been shown to predict adverse maternal/perinatal outcomes. This study explored the outcomes of hypertensive pregnancies using sFlt1/PlGF ratio in the third trimester. A single site prospective cohort study was done at a tertiary center in India. Singleton pregnancies with chronic/gestational HTN between 28 and 37 weeks were enrolled. sFlt1/PlGF was measured in serum samples on Roche platform. The results were stratified as Screen negative, Borderline positive or Screen positive (Table 1). All patients were delivered based on clinical parameters. Data on 31 pregnancies (resulting in 85 samples) was analyzed using sFlt1/PlGF ratio (cases) and compared with 93 contemporaneous pregnancies who were monitored without the biomarkers (controls).With the biomarkers, there was an increase in diagnosis of preeclampsia and IUGR along with higher rates of preterm delivery less than 30 weeks with an increase in the NICU stay. However, there was a significant reduction in rates of adverse maternal outcomes. 9 cases with maternal (peripartum) complications in controls included 2 cases of abruption, 6 cases of HELLP/partial HELLP and 1 case of pulmonary edema as compared to only 1 case of pulmonary edema among cases. No cases of IUFD was reported with biomarkers (Table 2). Serial testing with sFlt1/PlGF in the third trimester could help avert serious adverse maternal and perinatal outcomes in hypertensive pregnancies. Larger prospective studies are needed.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call